查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1500411

HIV 疫苗市場：按階段、類別、抗體和最終用戶 - 2024-2030 年全球預測

HIV Vaccines Market by Phase (Phase I, Phase II, Phase III), Category (Preventive Vaccines, Therapeutic Vaccines), Antibodies, End Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年愛滋病疫苗市場規模為8.3508億美元，預計2024年將達到9.4005億美元，2030年將達到19.5126億美元，複合年成長率為12.88%。

HIV疫苗涉及旨在預防人類免疫力缺乏病毒（HIV）感染的疫苗的研究、開發和商業化，該病毒會導致後天免疫力缺乏症候群（AIDS）。 HIV疫苗旨在透過誘導免疫系統對抗HIV的早期階段來顯著減少新感染的數量。全球愛滋病毒感染者人數不斷增加是愛滋病毒疫苗開發和需求的主要驅動力。隨著越來越多的人被診斷出感染愛滋病毒，尋找有效預防措施的迫切性也隨之增加，推動了疫苗開發的研究和投資。此外，政策和法律規範也為推動愛滋病毒疫苗研究做出了重大貢獻。政府和國際衛生組織經常提供資金，簡化核准流程，並制定潛在疫苗的研究、測試和分發指南。然而，藥品核准的嚴格監管對企業來說是困難的，也是市場擴張的主要障礙。此外，藥物配方和藥物傳遞系統的進步將提高針對愛滋病毒病理學至關重要的病毒成分的精確度和效率。

主要市場統計
基準年[2023] 83508萬美元
預測年份 [2024] 94005萬美元
預測年份 [2030] 1,951.26 百萬美元
複合年成長率（%） 12.88%

區域洞察

在美洲，特別是在美國，美國國立衛生研究院等聯邦機構和私人基金會正在對愛滋病毒疫苗的研究和開發進行大量投資。消費者對愛滋病毒及其預防的認知度較高，有效的疫苗接種方案正在獲得越來越多的接受和需求。美國持有多項愛滋病疫苗技術專利，體現了美國國內強大的創新能力。同時，加拿大也呈現與美國類似的模式，其認知度很高，醫療基礎設施先進，支持愛滋病疫苗的開發。加拿大消費者普遍了解愛滋病毒/愛滋病，一旦疫苗獲得核准，這就會轉化為對參與疫苗試驗和免疫計畫的積極態度。歐盟國家提供多樣化且普遍高水準的醫療保健和愛滋病毒預防服務，包括正在進行的愛滋病毒疫苗試驗。歐盟也受益於鼓勵跨境投資和研究共用、支持有效疫苗開發的合作框架。由於文化和社會規範強烈影響包括疫苗接種在內的健康相關行為，中東和非洲是一個複雜的市場。對愛滋病毒的認知和教育因地區而異，這影響著消費者對疫苗接種工作的反應。此外，由於醫療保健投資的增加和注重健康的消費者群體的不斷成長，亞太地區呈現出充滿活力的市場潛力。中國和印度等國家至關重要，因為它們人口眾多，政府也越來越重視公共衛生工作。該地區的愛滋病毒疫苗研究正在蓬勃發展，最近的專利和政府資助的計劃表明該地區有潛力引領該領域的創新。公共衛生部門對愛滋病毒預防措施的興趣日益濃厚，推動了消費者接種疫苗的意願。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在 HIV 疫苗市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對愛滋病毒疫苗市場供應商的現狀進行深入而詳細的評估。對供應商貢獻的徹底比較和分析可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在愛滋病毒疫苗市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地對愛滋病的認知不斷提高，對有效治療的需求也隨之增加。
      • 政府對愛滋病毒藥物的支持框架與政策
      • 政府和非政府組織加強宣傳活動，提高人們對愛滋病毒流行的認知
    • 抑制因素
      • 與愛滋病毒疫苗商業化和標準化相關的嚴格法規
    • 機會
      • CRISPR 基因編輯和人工智慧驅動的 HIV 預測模型的創新
      • 政府機構和生技公司之間的研發合作關係增加
    • 任務
      • 藥品配方的複雜性和產品召回案例
  • 市場區隔分析
    • 階段：分幾個階段對愛滋病毒疫苗進行嚴格測試，以確保公眾健康
    • 最終用戶：在公共保健機構中廣泛使用愛滋病毒疫苗以控制和消除愛滋病毒流行
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 HIV 疫苗市場：依階段

  • 第一階段
  • 第二階段
  • 第三階段

第7章 HIV 疫苗市場：依類別

  • 預防性疫苗
  • 治療性疫苗

第8章 HIV 疫苗市場：依抗體分類

  • 10E8
  • 廣泛中和抗體
  • PG9 和 PG16
  • VRC01

第9章 HIV 疫苗市場：依最終用戶分類

  • 臨床研究中心
  • 醫院
  • 公立醫療機構

第10章美洲HIV疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太HIV疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲HIV疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Uvax Bio 在澳洲透過臨床試驗推進 HIV 疫苗的開發
    • FDA核准新型 HIV 疫苗 HB-500 的人體試驗
    • Absci 與加州理工學院創新合作開發經濟實惠的 HIV 治療疫苗
  • 戰略分析和建議

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4312A385A507

[185 Pages Report] The HIV Vaccines Market size was estimated at USD 835.08 million in 2023 and expected to reach USD 940.05 million in 2024, at a CAGR 12.88% to reach USD 1,951.26 million by 2030.

The HIV vaccine pertains to the research, development, and commercialization of vaccines that are aimed at preventing the infection caused by the Human Immunodeficiency Virus (HIV) responsible for Acquired Immunodeficiency Syndrome (AIDS). HIV vaccines aim to reduce the number of new infections significantly by inducing the immune system to fight the early stages of HIV. The growing number of HIV cases worldwide acts as a primary driver for the development and demand for HIV vaccines. As more individuals are diagnosed with HIV, there is a heightened urgency to find effective preventive measures, propelling research and investment into vaccine development. In addition, supportive policies and regulatory frameworks contribute significantly to advancing HIV vaccine research. Governments and international health organizations often provide funding, streamline approval processes, and establish guidelines for researching, testing, and distributing potential vaccines. However, strict regulations regarding drug approvals can be challenging for companies and significantly hinder market expansion. Moreover, advancement in the drug formulation along with the drug delivery system improves the accuracy and efficiency of targeting viral components critical to HIV's pathology.

KEY MARKET STATISTICS
Base Year [2023] USD 835.08 million
Estimated Year [2024] USD 940.05 million
Forecast Year [2030] USD 1,951.26 million
CAGR (%) 12.88%

Regional Insights

In the Americas, particularly in the United States, significant investment has been channeled into research and development of HIV vaccines, driven by both federal agencies such as NIH and private foundations. Consumer awareness regarding HIV and its prevention is relatively high, leading to a stronger acceptance and demand for effective vaccination solutions. The US holds numerous patents related to HIV vaccine technologies, reflecting robust innovation within the country. At the same time, Canada shows a pattern similar to the United States, with high awareness and advanced healthcare infrastructure supporting HIV vaccine development. Canadian consumers are generally well-informed about HIV/AIDS, which corresponds to positive attitudes toward participating in vaccine trials and immunization programs once a vaccine is approved. Countries within the EU have diverse and generally high levels of healthcare provision and access to HIV prevention services, including ongoing trials for HIV vaccines. The EU also benefits from collaborative frameworks that facilitate investment and research sharing across borders, boosting the development of effective vaccines. The Middle East and Africa present a complex market due to the cultural and social norms that significantly influence health-related behavior, including vaccination. Awareness and education about HIV are varied across the region, which impacts consumer response to vaccination initiatives. Moreover, the Asia Pacific region demonstrates dynamic market potential with increasing healthcare investments and a growing consumer base that is becoming more health-conscious. Nations, including China and India, are pivotal due to their substantial populations and increasing government focus on public health initiatives. The region has ramped up HIV vaccine research and holds potential for leading innovations in this field, underscored by recent patents and government-funded projects. There's a growing public health focus on preventive measures against HIV, which bolsters consumer openness to vaccination.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the HIV Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing awareness about AIDS worldwide and the need for effective medications
      • Supportive government frameworks and policies for HIV drugs
      • Increasing number of government and NGO campaigns for awareness of the HIV epidemic
    • Market Restraints
      • Strict regulations associated with the commercialization and standardization of HIV vaccines
    • Market Opportunities
      • Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
      • Increasing number of R&D partnerships between government bodies and biotechnology firms
    • Market Challenges
      • Complexities associated with drug formulation and cases of product recalls
  • Market Segmentation Analysis
    • Phase: Rigorous testing of HIV vaccines through several phases to ensure public health
    • End Users: Extensive usage of HIV vaccines in public healthcare facilities to control and combat the HIV epidemic
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the HIV Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the HIV Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Uvax Bio Progresses HIV Vaccine Development with Australian Clinical Trial

Uvax Bio, LLC, a clinical-stage vaccine company, has received approval from the Australian Therapeutic Goods Administration and the Human Research Ethics Committee to begin a Phase 1 trial of their innovative HIV-1 vaccines, UVAX-1197 and UVAX-1107, in Australia. The study will leverage Uvax Bio's unique 1c-SApNP technology, which utilizes two forms of the HIV envelope protein configurations. [Published On: 2023-12-19]

FDA Approves Novel HIV Vaccine, HB-500 Vaccine for Human Testing

HOOKIPA Pharma Inc. secured FDA approval to proceed with clinical trials for HB-500, an innovative therapeutic vaccine aimed at treating HIV. This vaccine utilizes an alternating two-vector system based on the lymphocytic choriomeningitis virus and the Pichinde virus, both carrying HIV antigens. This unique dual-vector approach is intended to enhance the immune system's response targeting HIV, potentially leading to significant therapeutic benefits. [Published On: 2023-11-20]

Innovative Collaboration Between Absci and Caltech to Develop Affordable HIV Therapeutic Vaccine

Absci Corporation, in partnership with the California Institute of Technology and funded by a substantial grant from the Bill & Melinda Gates Foundation, is pioneering a novel approach to HIV therapy. The project harnesses advanced technologies in structural biology, protein design, and generative AI to create a novel HIV therapeutic vaccine. This initiative aims to develop a therapy that targets a highly conserved epitope on HIV-1, potentially offering both treatment and protection against all strains of the virus. [Published On: 2023-08-17]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the HIV Vaccines Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the HIV Vaccines Market, highlighting leading vendors and their innovative profiles. These include AlphaVax, Inc., Antigen Express, Inc. by Generex Biotechnology Corporation, Argos Therapeutics, Inc., Bavarian Nordic, Bionor Holding AS, Celldex Therapeutics, Inc., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline PLC, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Moderna Inc., Novartis AG, Oncolys BioPharma Inc., Sanofi S.A., and TVAX Biomedical, Inc..

Market Segmentation & Coverage

This research report categorizes the HIV Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Phase
    • Phase I
    • Phase II
    • Phase III
  • Category
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Antibodies
    • 10E8
    • Broadly Neutralizing Antibodies
    • PG9 and PG16
    • VRC01
  • End Users
    • Clinical Research Centers
    • Hospitals
    • Public Healthcare Providers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness about AIDS worldwide and the need for effective medications
      • 5.1.1.2. Supportive government frameworks and policies for HIV drugs
      • 5.1.1.3. Increasing number of government and NGO campaigns for awareness of the HIV epidemic
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations associated with the commercialization and standardization of HIV vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
      • 5.1.3.2. Increasing number of R&D partnerships between government bodies and biotechnology firms
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with drug formulation and cases of product recalls
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Rigorous testing of HIV vaccines through several phases to ensure public health
    • 5.2.2. End Users: Extensive usage of HIV vaccines in public healthcare facilities to control and combat the HIV epidemic
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. HIV Vaccines Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III

7. HIV Vaccines Market, by Category

  • 7.1. Introduction
  • 7.2. Preventive Vaccines
  • 7.3. Therapeutic Vaccines

8. HIV Vaccines Market, by Antibodies

  • 8.1. Introduction
  • 8.2. 10E8
  • 8.3. Broadly Neutralizing Antibodies
  • 8.4. PG9 and PG16
  • 8.5. VRC01

9. HIV Vaccines Market, by End Users

  • 9.1. Introduction
  • 9.2. Clinical Research Centers
  • 9.3. Hospitals
  • 9.4. Public Healthcare Providers

10. Americas HIV Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific HIV Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa HIV Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Uvax Bio Progresses HIV Vaccine Development with Australian Clinical Trial
    • 13.3.2. FDA Approves Novel HIV Vaccine, HB-500 Vaccine for Human Testing
    • 13.3.3. Innovative Collaboration Between Absci and Caltech to Develop Affordable HIV Therapeutic Vaccine
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. HIV VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HIV VACCINES MARKET DYNAMICS
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY 10E8, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY 10E8, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY BROADLY NEUTRALIZING ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY BROADLY NEUTRALIZING ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY PG9 AND PG16, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY PG9 AND PG16, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY VRC01, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY VRC01, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICAL RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICAL RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTHCARE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTHCARE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 351. TURKEY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 352. TURKEY HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 357. TURKEY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 358. TURKEY HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 368. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2023 (USD MILLION)
  • TABLE 370. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2024-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2023 (USD MILLION)
  • TABLE 372. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2024-2030 (USD MILLION)
  • TABLE 373. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
  • TABLE 374. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
  • TABLE 375. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 376. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023